Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Recurrent Malignant Glioma Trials

Survivors of Glioblastoma GBM Changes in the Gene Expression Profile in Original tumor and recurrence. (IRB: 1110-0209) – Investigator Initiated

Principal Investigator: Pamela New, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800 3 MNI Neuro-Oncology Clinical Trials 2012
Description: The study will assess the molecular phenotype of ten patients who responded to standard treatment and survived glioblastoma in excess of 24 months from original diagnosis. A profile was also obtained at the time of recurrence in an effort to detect genetic changes which may be predictive of survival. The profiles will be completed by Castle Biosciences.
Status: Active

Ask a question or refer a patient.

COGLI Trial: Phase I/II Administration of CMV-specific cytotoxic T cells in patients with Glioblastoma multiforme: Cell and Gene Therapy Trial

Principal Investigator: Stephen Gottschalk, M.D. & Pamela New, M.D., Nabil Ahmed, M.D, Robert Grossman, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The purpose of this study is to find the largest safe dose of CMV-T cells using patient's own immune cells, to learn what the side effects are, and to see whether this therapy might help patients with Gliomblastoma. CMV is found in the majority of Glioblastomas and thus serves as an attractive target for cellular therapies.
Status: Active

Ask a question or refer a patient.

BTTC 11-02: Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma

Principal Investigator: Pamela New, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The purpose of this Phase II clinical research study is to learn if Bevacizumab when given with or without vorinostat can help to control malignant gliomas. The safety of these drug combinations, which is investigational will also be studied. Both Virnostat and Bevacizumab are chemotherapy drugs that are used to slow the growth of cancer.

The Brain Tumor Trials Collaborative (BTTC) was created as a network of medical centers with the expertise and the strong desire to participate in state-of-the-art clinical trials investigating new treatments for malignant brain tumors. The University of Texas MD Anderson Cancer Center serves as the lead institution and provides the administrative infrastructure, the clinical database and oversight for the collaborative. Twenty two other centers have joined the BTTC. Together with MD Anderson, these institutions will allow patients across a broad geographic range to participate in these cutting-edge clinical trials and more rapidly determine the benefits of these therapies.
Status: Active

Ask a question or refer a patient.

HERT-GBM Trial: Phase I/II Administration of CMV- HER2- bispecific cytotoxic T cells in patients with Glioblastoma: Cell and Gene Therapy Trial

Principal Investigator: Pamela New, M.D., Robert Grossman, M.D, Nabil Ahmed, M.D., Stephen Gottschalk, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The purpose of this study is to find the largest safe dose of CMV- HER2- bispecific cytotoxic T cells using patient's own immune cells, to learn what the side effects are, and to see whether this therapy might help patients with Gliomblastoma. CMV and HER2 are present in the majority of Glioblastomas and targeting both antigens simultaneously represents an effective way for tumor control.

Ask a question or refer a patient.


BTTC 09-01: A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High Grade Gliomas

Principal Investigator: Pamela New, M.D.
Study Coordinator: Kimbra Harris Phone Number: 713-441-3800
Description: The goal of Phase I of this clinical research study is to find the highest tolerable dose and best schedule of the combination of Everolimus and Sorafenib that can be given to patients with malignant glioma. The goal of Phase II of this study to learn if the combination of Everolimus and Sorafenib can help to control malignant glioma. The safety of this combination will also be studied in both phases.

The Brain Tumor Trials Collaborative (BTTC) was created as a network of medical centers with the expertise and the strong desire to participate in state-of-the-art clinical trials investigating new treatments for malignant brain tumors. The University of Texas MD Anderson Cancer Center serves as the lead institution and provides the administrative infrastructure, the clinical database and oversight for the collaborative. Twenty two other centers have joined the BTTC. Together with MD Anderson, these institutions will allow patients across a broad geographic range to participate in these cutting-edge clinical trials and more rapidly determine the benefits of these therapies.

Ask a question or refer a patient.

How Can We Help?
Call us